



August 20, 2019

AccuRna signs Feasibility Study Agreement with Astellas Innovation Management LLC

AccuRna Inc. (Tokyo, JAPAN, "AccuRna") today announced that the company enters into a Feasibility Study Agreement with Astellas Innovation Management LLC (Cambridge, MA, USA.) subsidiary of Astellas Pharma Inc for the use of delivery system of polymer micelle¹ loaded with messenger RNA (mRNA) under pre-clinical development by AccuRna.

AccuRna will continue non-clinical development toward clinical application of delivery system of polymer micelle loaded with mRNA.

About AccuRna Inc.

AccuRna Inc. has established in December 2015 with a mission to achieve the practical use of the "RNA delivery system", which is the research result of Prof. Kazunori Kataoka, Professor Emeritus of The University of Tokyo, Director general of Innovation Center of NanoMedicine Kawasaki Institute of Industrial Promotion.

The goal of the company is to provide new nucleic acid medicine to patients suffering from underserved disease with high unmet needs through our internal development effort on pipeline based on aforementioned proprietary platform technology and external collaboration by applying these platform technologies to nucleic acid drug owned by our partners.

For detailed information, please refer to <https://accurna.com/>

Contact Information

<https://accurna.com/contact-us/>

¹ Nanoparticles formed by aggregation of a block copolymer consisting of two blocks of a hydrophilic polymer (such as polyethylene glycol) and a functional polymer (such as a polyamino acid derivative) whose hydrophobicity and charge are controlled. It has a two-layer structure that can contain drugs and nucleic acids, and is surrounded by an outer shell of a hydrophilic polymer.